Search

Displaying results 3901 - 3910 of 10000 in total
  1. Drug

    Zansecimab

    go.drugbank.com/drugs/DB16389
    Investigational

    Zansecimab is under investigation in clinical trial NCT04342897 (A Study of LY3127804 in Participants With COVID-19).

  2. Drug

    NM-702

    go.drugbank.com/drugs/DB05505
    Investigational

    Intermittent claudication is a major symptom of arteriosclerosis obliterans. … M-702 is an orally active inhibitor of phosphodiesterase and thromboxane synthetase.

    Categories: Heterocyclic Compounds, 1-Ring
  3. Drug

    Odanacatib

    go.drugbank.com/drugs/DB06670
    Investigational

    Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388].

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  4. Drug

    NCX 1022

    go.drugbank.com/drugs/DB05410
    Experimental

    NCX is an NO-releasing derivative of hydrocortisone.

  5. Drug

    Loxapine

    go.drugbank.com/drugs/DB00408
    ApprovedInvestigational

    An antipsychotic agent used in schizophrenia. [PubChem]

    Synonyms: 2-Chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepineCategories: P-glycoprotein inhibitors, Heterocyclic Compounds, 3-Ring
  6. Drug

    Sitaxentan

    go.drugbank.com/drugs/DB06268
    ApprovedWithdrawn

    Sitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan f...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Inhibitors
  7. Drug

    Azvudine

    go.drugbank.com/drugs/DB16407
    Investigational

    Azvudine is under investigation in clinical trial NCT04668235 (Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (Sars-cov-2 Infected)).

    Categories: Heterocyclic Compounds, 1-Ring
  8. Drug

    Ciluprevir

    go.drugbank.com/drugs/DB05868
    Investigational

    The compound, named BILN 2061, is an orally active inhibitor of the HCV NS3 protease and the first member of this new drug class to be tested in humans.

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  9. Drug

    ATN-161

    go.drugbank.com/drugs/DB05491
    Investigational

    ATN-161 is a non-RGD based integrin binding peptide targeting alpha-5 beta-1 and alpha-v beta-3. … Since the expression of alpha(5)beta(1) integrin by cancer cells and the role of this molecule in tumor angiogenesis is similar across a range of different cancers, the therapeutic benefit of ATN-161 is

  10. Drug

    GS-441524

    go.drugbank.com/drugs/DB15686
    Investigational

    [L13775] _In vitro_ studies of GS-441524 have determined it has a higher EC<sub>50</sub> than remdesivir against a number of viruses, meaning GS-441524 is less potent. … GS-441524 is an adenosine nucleotide analog antiviral, similar to [remdesivir].[A203057,L13239] This molecule was patented in 2009.

    Categories: Heterocyclic Compounds, 2-Ring